BR112015031040A8 - Novos moduladores do receptor de glp-1 - Google Patents

Novos moduladores do receptor de glp-1

Info

Publication number
BR112015031040A8
BR112015031040A8 BR112015031040A BR112015031040A BR112015031040A8 BR 112015031040 A8 BR112015031040 A8 BR 112015031040A8 BR 112015031040 A BR112015031040 A BR 112015031040A BR 112015031040 A BR112015031040 A BR 112015031040A BR 112015031040 A8 BR112015031040 A8 BR 112015031040A8
Authority
BR
Brazil
Prior art keywords
glp
peptide
new
methods
new glp
Prior art date
Application number
BR112015031040A
Other languages
English (en)
Other versions
BR112015031040A2 (pt
Inventor
F Boehm Marcus
Huang Liming
Martinborough Esther
Moorjani Manisha
Tamiya Junko
r yeager Adam
Brahmachary Enugurthi
Fowler Thomas
Novak Andrew
Meghani Premji
Knaggs Michael
Original Assignee
Receptos Inc
Receptos Llc
Celgene Int Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptos Inc, Receptos Llc, Celgene Int Ii Sarl filed Critical Receptos Inc
Publication of BR112015031040A2 publication Critical patent/BR112015031040A2/pt
Publication of BR112015031040A8 publication Critical patent/BR112015031040A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

NOVOS MODULADORES DO RECEPTOR DE GLP-1 (I) O documento provê compostos que modulam o receptor do peptídeo 1 semelhante ao glucagon, bem como métodos de síntese e métodos para emprego terapêutico e/ou profilático dos mesmos. Tais compostos podem atuar como moduladores ou potenciadores do receptor de GLP-1 propriamente ou com peptídeos de incretina, tais como, GLP-1 (7-36) e GLP-1 (9-36) ou com terapias à base de peptídeo, tais como, exanatide e liraglutide e possui a estrutura da fórmula geral acima (onde "(I)" representa tanto uma ou ambas as formas R e S do composto): em que A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p e q são conforme definidos no presente documento.
BR112015031040A 2013-06-11 2014-06-11 Novos moduladores do receptor de glp-1 BR112015031040A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833737P 2013-06-11 2013-06-11
US201461981643P 2014-04-18 2014-04-18
PCT/US2014/041997 WO2014201172A1 (en) 2013-06-11 2014-06-11 Novel glp-1 receptor modulators

Publications (2)

Publication Number Publication Date
BR112015031040A2 BR112015031040A2 (pt) 2017-07-25
BR112015031040A8 true BR112015031040A8 (pt) 2018-01-02

Family

ID=51136825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031040A BR112015031040A8 (pt) 2013-06-11 2014-06-11 Novos moduladores do receptor de glp-1

Country Status (13)

Country Link
US (3) US9260427B2 (pt)
EP (1) EP3008056B8 (pt)
JP (1) JP6573604B2 (pt)
KR (1) KR102271179B1 (pt)
CN (2) CN105593225B (pt)
AU (1) AU2014278183B2 (pt)
BR (1) BR112015031040A8 (pt)
CA (1) CA2913791A1 (pt)
EA (1) EA030857B1 (pt)
ES (1) ES2864349T3 (pt)
HK (2) HK1222176A1 (pt)
MX (1) MX370666B (pt)
WO (1) WO2014201172A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166951A1 (en) 2011-05-31 2012-12-06 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
RU2634896C2 (ru) 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
EP3008056B8 (en) 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
JP2017538711A (ja) * 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル Ｇｌｐ−１レセプターモジュレーター
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
JP6878615B2 (ja) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
AU2018260686B2 (en) * 2017-04-28 2022-03-17 Receptos Llc Novel GLP-1 receptor modulators
CN109608524B (zh) * 2018-11-09 2022-06-03 北京志道生物科技有限公司 兼具dpp-4抑制及glp1r激活活性的多肽衍生物、制备和应用
CN111548311B (zh) * 2020-06-04 2021-04-23 山西医科大学 一种小分子glp-1r激动剂及其应用
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114989204A (zh) * 2022-06-16 2022-09-02 西北工业大学 一种葡萄糖响应自修复凝胶用的二苯乙炔类液晶态交联剂的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
BR9407933A (pt) * 1993-11-01 1996-11-26 Japat Ltd Antagonistas de receptores de endotelina
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
KR20010022405A (ko) * 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CA2301377C (en) 1997-08-22 2009-10-06 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
BR9811988A (pt) * 1997-08-22 2000-09-05 Hoffmann La Roche Derivados de n-alcanoilfenilalanina
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
JP4245682B2 (ja) * 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
EP1992641A3 (en) 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
EP1609478A1 (en) 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. Exendin agonist peptide formulations
EP1150565A1 (en) * 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
JP3795305B2 (ja) * 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
EP1233013B1 (en) * 1999-11-18 2007-02-28 Ajinomoto Co., Inc. Novel phenylalanine derivatives
BR0016172A (pt) * 1999-12-06 2002-08-20 4-piridinil-n-acil-l-fenilalaninas
HUP0302772A3 (en) 2000-03-07 2007-03-28 Sanofi Aventis Deutschland Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
SI1288205T1 (sl) * 2000-08-18 2011-05-31 Ajinomoto Kk Novi derivati fenilalanina
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003053926A1 (fr) * 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Nouveau derive de phenylalanine
WO2003070709A1 (fr) * 2002-02-20 2003-08-28 Ajinomoto Co.,Inc. Nouveau derive de phenylalanine
JPWO2003089410A1 (ja) * 2002-04-19 2005-08-25 協和醗酵工業株式会社 フェニルアラニン誘導体
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
CN101386600B (zh) * 2003-02-20 2011-07-06 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
ZA200600059B (en) 2003-06-13 2007-04-25 S A L V A T Lab Sa New benzamides as prary modulators
BRPI0418026A (pt) 2003-12-22 2007-04-17 Ajinomoto Kk derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
KR20070004676A (ko) * 2004-02-10 2007-01-09 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논
JP2005263787A (ja) * 2004-02-17 2005-09-29 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2006117743A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2402326A1 (en) * 2005-06-21 2012-01-04 Ajinomoto Co., Inc. Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors
CN101360711A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-苯丙氨酸衍生物及其作为整联蛋白拮抗剂的用途
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
EP2103601B1 (en) * 2006-11-22 2012-03-14 Ajinomoto Co., Inc. Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
WO2008064823A1 (en) * 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008112938A2 (en) 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
CN101679365A (zh) 2007-06-08 2010-03-24 艾德维纳斯医疗私人有限公司 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用
EP2205085A1 (en) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2993173A1 (en) * 2010-03-29 2016-03-09 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
EP2579888A2 (en) 2010-06-09 2013-04-17 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
WO2012166951A1 (en) 2011-05-31 2012-12-06 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
RU2634896C2 (ru) 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
EP3008056B8 (en) 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).

Also Published As

Publication number Publication date
CA2913791A1 (en) 2014-12-18
CN109867630A (zh) 2019-06-11
US20170313717A1 (en) 2017-11-02
KR20160042868A (ko) 2016-04-20
EA201592281A1 (ru) 2016-05-31
US10259823B2 (en) 2019-04-16
EP3008056B8 (en) 2021-03-03
BR112015031040A2 (pt) 2017-07-25
HK1222177A1 (zh) 2017-06-23
JP6573604B2 (ja) 2019-09-11
EP3008056A1 (en) 2016-04-20
CN105593225A (zh) 2016-05-18
US9598430B2 (en) 2017-03-21
US20160214993A1 (en) 2016-07-28
EP3008056B1 (en) 2020-12-09
MX370666B (es) 2019-12-19
MX2015016831A (es) 2016-04-04
EA030857B1 (ru) 2018-10-31
HK1222176A1 (zh) 2017-06-23
US9260427B2 (en) 2016-02-16
ES2864349T3 (es) 2021-10-13
AU2014278183B2 (en) 2018-10-04
CN105593225B (zh) 2019-04-16
AU2014278183A1 (en) 2016-01-07
US20150011527A1 (en) 2015-01-08
WO2014201172A1 (en) 2014-12-18
KR102271179B1 (ko) 2021-07-01
JP2016528180A (ja) 2016-09-15
NZ715006A (en) 2021-02-26

Similar Documents

Publication Publication Date Title
BR112015031040A8 (pt) Novos moduladores do receptor de glp-1
BR112014013925A2 (pt) novos moduladores do receptor de glp-1
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
CY1122539T1 (el) Αναλογα γλυκαγονης
CY1122754T1 (el) Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r
EA201992327A1 (ru) Пептид, активирующий рецептор гип
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
MX2019010531A (es) Compuesto peptidico.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
EA201991345A1 (ru) Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
ECSP12012181A (es) Nuevos péptidos y métodos para su preparación y uso
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2017007494A (es) Moduladores del receptor de peptido 1 tipo glucagon.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: RECEPTOS, LLC. (US)

B25A Requested transfer of rights approved

Owner name: CELGENE INTERNATIONAL II SARL (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: RECEPTOS LLC (US)